Refractive surgery

CorNeat EverPatch Hits the US Market: Farewell to Traditional Ocular Tissue Grafts

Retrieved on: 
Tuesday, February 27, 2024

RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- CorNeat Vision, a leader in innovative medical device solutions, proudly introduces the CorNeat EverPatch, a pioneering synthetic tissue-integrating matrix designed to revolutionize ophthalmic surgeries. Endorsed by leading surgeons across the US, this FDA-cleared device represents a significant leap forward in addressing complications related to surgical interventions of the ocular surface.

Key Points: 
  • The CorNeat EverPatch is a synthetic tissue substitute for ocular surface surgeries, offering a unique combination of features that provide a significant advantage over existing tissue grafts, which degrade over time.
  • The CorNeat EverPatch is poised to provide an optimal solution for reinforcing tissue over glaucoma drainage devices, addressing complications such as tube exposure that often require reoperation.
  • Dr. Gilad Litvin, Co-Founder and Chief Medical Officer at CorNeat Vision, emphasizes the safety and efficacy of the CorNeat EverPatch, stating, "Our synthetic tissue substitute is tear-resistant, non-degradable, and completely bio-compatible, with no observed chronic inflammatory response that exists around tissue grafts.
  • We are confident that the CorNeat EverPatch will set a new standard of care in ocular surgeries necessitating scleral reinforcement."

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Thursday, February 1, 2024

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.

STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision

Retrieved on: 
Tuesday, January 23, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240123947715/en/
    STAAR Surgical and SharpeVision will collaborate on marketing and education activities to elevate awareness of EVO ICL and significantly increase availability of the lenses to all qualified patients in SharpeVision clinics.
  • STAAR Surgical will also provide additional practice development and clinical support.
  • “We are pleased to announce SharpeVision as a new partner under our U.S. Highway 93 go-to-market program initiated in October 2023.
  • Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery.

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Retrieved on: 
Thursday, December 28, 2023

The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.

Key Points: 
  • The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.
  • By retiring the LCDs, the MACs have supported continued access to advanced patient care like MPTLT,” said David I. Bruce, President & CEO, Iridex Corporation.
  • Between October 24th, 2023 and November 9th, 2023, five of the seven MACs published LCDs targeting MIGS procedures, which also partially restricted criteria for coverage of cyclophotocoagulation reimbursement.
  • As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with Iridex MicroPulse® TLT.

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Retrieved on: 
Thursday, December 28, 2023

MENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their final local coverage determinations (“LCDs”) for Micro-Invasive Glaucoma Surgery (“MIGS”) that were scheduled to take effect on January 29, 2024.

Key Points: 
  • MENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their final local coverage determinations (“LCDs”) for Micro-Invasive Glaucoma Surgery (“MIGS”) that were scheduled to take effect on January 29, 2024.
  • All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024.
  • As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with the OMNI Surgical System.
  • Additionally, we appreciate the support from the Medical Device Manufacturers Association (MDMA) and numerous patient advocacy groups.”

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Retrieved on: 
Monday, October 30, 2023

Dr. Baldwin will present on Thursday, November 2nd at 1:36pm PST as part of Eyecelerator’s “Retina Showcase” highlighting companies advancing next generation therapeutics for retina diseases.

Key Points: 
  • Dr. Baldwin will present on Thursday, November 2nd at 1:36pm PST as part of Eyecelerator’s “Retina Showcase” highlighting companies advancing next generation therapeutics for retina diseases.
  • Eyecelerator is a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS).
  • Its mission is to connect entrepreneurs, investors, companies, and physicians to advance ophthalmic innovation through live conferences, virtual programming, and a next-generation networking platform.
  • The Academy innovates to advance the profession and to ensure the delivery of the highest-quality eye care.

Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific Committee

Retrieved on: 
Monday, October 30, 2023

DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.
  • “We are truly honoured that Dr. Ahmed has agreed to join Hexiris Pharma’s Scientific Committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris Pharma.
  • I’m pleased to be joining the Scientific Committee at Hexiris Pharma and join in the important work of improving the lives of patients and bringing new solutions and opportunities to ophthalmologists,” said Dr. Ahmed.
  • He has given over 750 scientific presentations thus far in his career, including 31 visiting professor’s lectures around the world.

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

Retrieved on: 
Monday, October 30, 2023

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP130007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that it is sponsoring a course during the International Joint Commission on Allied Health Personnel in Ophthalmology (IJCAHPO) 51st Annual Continuing Education (ACE) program, which is being held November 3-5 in San Francisco.

Key Points: 
  • The course, Topical Pharmaceutical Drug Delivery Innovations: The Potential Role for the New Ophthalmic Spray, will offer ophthalmic technicians background on Eyenovia’s Optejet dispensing technology and training on the use of Mydcombi in daily practice.
  • “We continue to ramp our internal manufacturing capabilities, staff our sales management team and obtain additional key state licenses of which we now have eight either completed or in process.
  • We look forward to transitioning to a broader commercial launch of Mydcombi in early 2024.”
    Topical Pharmaceutical Drug Delivery Innovations: The Potential Role for the New Ophthalmic Spray
    Francis Mah, M.D., Director of Cornea and External Disease and the Co-Director, Refractive Surgery at Scripps Clinic.
  • In addition, Mydcombi was featured in a white paper on Touch Ophthalmology, Pharmacologic Mydriasis and Cycloplegia: A Review of Novel Delivery Devices, which can be accessed here .

Implandata Announces Appointment of New Members Dr. Adrienne Graves and Jan Willem de Cler to Join Board of Directors

Retrieved on: 
Tuesday, October 24, 2023

HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata. As the former CEO of Santen Inc., she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and commercialization and leading global teams through successful acquisitions and partnerships. Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in research and development, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as a director on the boards of various ophthalmic pharmaceutical and health-tech companies. She serves on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund. Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders).

Key Points: 
  • Jan Willem de Cler will also take over responsibility as Chairman of the Board.
  • HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata.
  • Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory.
  • Jan Willem studied Business Administration at Nijenrode University in the Netherlands and the University of Oregon, USA where he accomplished his MBA.

Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL

Retrieved on: 
Tuesday, October 10, 2023

This partnership brings together EVO Implantable Collamer® Lenses (EVO ICL) for nearsightedness and astigmatism and the voice of Jimmy O. Yang.

Key Points: 
  • This partnership brings together EVO Implantable Collamer® Lenses (EVO ICL) for nearsightedness and astigmatism and the voice of Jimmy O. Yang.
  • The EVO ICL vision correction procedure has been a life-changing experience for him.
  • "Like with Jimmy O. Yang, I am seeing an increasing number of patients who qualify for both EVO ICL and laser vision correction opting for the lens-based surgery.
  • EVO ICL represents a significant advancement in vision correction technology as it works in harmony with the natural eye.